Several DPP-4 inhibitors (also known as gliptins) have been approved in the US, Europe, Japan, and South Korea to treat T2D, which are supposed to augment the bioavailability of incretin hormones, prolong the action of insulin, and thus provide benefits on postprandial glucose response [137]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.